Continuous Passive Motion Devices Market - Global Forecast 2026-2032

The Continuous Passive Motion Devices Market size was estimated at USD 966.06 million in 2025 and expected to reach USD 1,024.61 million in 2026, at a CAGR of 6.77% to reach USD 1,528.66 million by 2032.

Continuous passive motion devices are rehabilitation systems designed to move a joint through a controlled range of motion without requiring active muscle effort from the patient. In orthopedic recovery, sports medicine, trauma rehabilitation, and postsurgical care, continuous passive motion devices support early mobilization protocols for knees, hips, shoulders, elbows, ankles, wrists, and hands. Demand is closely tied to the global volume of joint replacement, ligament repair, cartilage restoration, fracture fixation, and reconstructive procedures.

The market is shaped by two verified healthcare realities: musculoskeletal conditions are among the leading contributors to disability worldwide, and population aging is increasing the number of patients at risk for osteoarthritis, joint stiffness, and mobility loss. The World Health Organization reports that musculoskeletal conditions affect approximately 1.71 billion people globally, while the United Nations expects the share of people aged 65 and older to continue rising through mid-century. These trends keep continuous passive motion equipment relevant in hospitals, ambulatory surgery centers, rehabilitation clinics, and home care programs focused on reducing stiffness, supporting range-of-motion recovery, and improving therapy adherence.

The continuous passive motion devices landscape is shifting from facility-centered therapy toward hybrid and home-based rehabilitation models. Shorter hospital stays, growth in ambulatory orthopedic procedures, and payer pressure to reduce avoidable readmissions are encouraging providers to adopt devices that can extend rehabilitation beyond the inpatient setting. This is particularly relevant for total knee arthroplasty, ligament reconstruction, and post-trauma immobilization cases where early, structured movement can be clinically useful when aligned with physician-directed protocols.

At the same time, the market is becoming more outcomes-driven. Clinical literature has produced mixed conclusions on routine continuous passive motion use after some procedures, especially uncomplicated total knee replacement, which has pushed manufacturers and care teams to emphasize patient selection, protocol customization, ease of setup, and measurable functional recovery. Competitive differentiation is increasingly based on portability, remote monitoring readiness, device ergonomics, rental logistics, infection-control design, and integration with broader physical therapy pathways rather than mechanical motion alone.

Artificial intelligence is beginning to influence continuous passive motion devices through rehabilitation personalization, predictive analytics, and connected care workflows. AI-enabled software can analyze usage patterns, range-of-motion progression, pain scores, adherence data, and recovery milestones to help clinicians adjust therapy plans. This supports a shift from fixed-duration protocols to more responsive rehabilitation models that reflect patient tolerance, surgical complexity, and comorbidity profiles.

The cumulative impact of AI is likely to be greatest where continuous passive motion devices are combined with sensors, telehealth, electronic health records, and remote patient monitoring. For manufacturers, AI can support preventive maintenance, device utilization forecasting, and rental fleet optimization. For providers, AI can help identify patients at risk of delayed recovery or nonadherence, enabling earlier intervention. Adoption will depend on data quality, cybersecurity, regulatory compliance, and clinical validation that AI-driven recommendations improve measurable rehabilitation outcomes.

Asia-Pacific is emerging as a high-growth region for continuous passive motion devices because of population aging, expanding orthopedic capacity, and rising procedure volumes in China, India, Japan, South Korea, and Australia. The region also benefits from growing private hospital networks and medical tourism in selected markets. North America remains a mature, innovation-led market supported by high orthopedic surgery utilization, established reimbursement systems, ambulatory surgery center expansion, and strong adoption of home rehabilitation solutions.

Latin America shows selective demand growth, led by Brazil and Mexico, as private healthcare investment and sports medicine programs expand, though public-sector budget constraints can limit device penetration. Europe demonstrates steady demand through advanced orthopedic care pathways, aging demographics, and rehabilitation standards across major healthcare systems. The Middle East, particularly higher-income Gulf markets, is investing in specialty hospitals and rehabilitation infrastructure, while Africa remains an early-stage opportunity where access to orthopedic surgery, device affordability, and rehabilitation workforce availability determine adoption.

ASEAN markets are benefiting from rising healthcare expenditure, expanding private hospitals, and a growing medical tourism base in countries such as Thailand, Malaysia, and Singapore, making the region attractive for portable and rental-based continuous passive motion devices. The GCC is prioritizing hospital modernization, specialty orthopedic centers, and post-acute rehabilitation capacity, creating opportunities for premium CPM systems and service-led distribution models.

The European Union provides a structured environment for certified medical devices, evidence-based rehabilitation, and cross-border regulatory consistency under the EU Medical Device Regulation. BRICS countries represent scale opportunities due to large patient populations, increasing orthopedic procedure capacity, and rising chronic disease burdens, although reimbursement and affordability vary widely. G7 markets remain central to innovation, clinical evidence generation, and premium device adoption, while NATO member countries overlap with many advanced healthcare systems where rehabilitation readiness, procurement transparency, and supply-chain resilience are increasingly important.

The United States leads demand for continuous passive motion devices through high orthopedic procedure volumes, a large ambulatory surgery center base, and strong home healthcare infrastructure, while Canada emphasizes regulated access, hospital procurement discipline, and rehabilitation quality. Mexico and Brazil are important Latin American markets where private hospitals, sports medicine, and orthopedic specialty services support adoption, although price sensitivity remains significant.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from aging populations and established rehabilitation pathways, with Germany standing out for orthopedic procedure intensity and medical technology adoption. Russia maintains demand through major urban healthcare centers but faces procurement and supply-chain complexity. In Asia-Pacific, China and India offer large-scale growth potential due to expanding surgical capacity and aging populations, Japan and South Korea show demand for advanced rehabilitation technologies in highly developed care systems, and Australia combines strong orthopedic access with home-based recovery models.

Industry leaders should align continuous passive motion device strategies with evidence-based care pathways rather than relying on one-size-fits-all rehabilitation claims. Manufacturers should invest in clinical validation, procedure-specific protocols, user-friendly interfaces, and connected features that help clinicians document adherence, range-of-motion gains, and therapy completion. Devices that reduce setup time, improve patient comfort, and support safe home use are best positioned for hospitals, ambulatory surgery centers, and rental providers.

Commercial teams should prioritize partnerships with orthopedic surgeons, physical therapists, home healthcare agencies, and durable medical equipment distributors. In mature markets, differentiation should focus on outcomes data, AI-enabled monitoring, service reliability, and reimbursement support. In emerging markets, leaders should emphasize affordability, training, maintenance support, and scalable rental models that expand access without requiring large upfront capital investment.

This executive summary is built on a structured research approach that combines secondary research, market mapping, clinical context assessment, and expert interpretation. Verified sources typically include public health databases, demographic projections, orthopedic procedure indicators, regulatory guidance, company disclosures, hospital procurement trends, and peer-reviewed clinical literature on postoperative rehabilitation and continuous passive motion use.

The methodology evaluates demand drivers such as musculoskeletal disease burden, aging population trends, surgical volumes, site-of-care shifts, reimbursement structures, and device innovation. Regional and country insights are assessed through healthcare infrastructure maturity, rehabilitation access, regulatory environment, affordability, and distribution readiness. Findings are triangulated to ensure that conclusions remain data-backed, commercially relevant, and aligned with real-world adoption conditions.

Continuous passive motion devices remain an important segment of orthopedic rehabilitation technology, especially where early mobilization, structured range-of-motion therapy, and home recovery support are prioritized. Market growth is supported by aging demographics, musculoskeletal disease prevalence, orthopedic procedure demand, and the transition toward outpatient and home-based care.

Future competitiveness will depend on evidence, connectivity, service models, and patient-centered design. Companies that combine clinically appropriate device use with AI-enabled monitoring, strong distribution networks, and measurable rehabilitation outcomes will be better positioned to capture demand across mature and emerging healthcare markets.